These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1059 related items for PubMed ID: 9489633

  • 1. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW.
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [Abstract] [Full Text] [Related]

  • 2. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation.
    Elmaagacli AH, Beelen DW, Becks HW, Mobascher A, Stockova J, Trzensky S, Opalka B, Schaefer UW.
    Bone Marrow Transplant; 1996 Aug; 18(2):397-403. PubMed ID: 8864452
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S, Barnett L, Heller G.
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [Abstract] [Full Text] [Related]

  • 9. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
    Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U.
    J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
    [Abstract] [Full Text] [Related]

  • 10. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R, Laczika K, Knöbl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B.
    Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
    [Abstract] [Full Text] [Related]

  • 11. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, Parziale A, Marmont F, Diverio D, Divona M, Lo Coco F, Saglio G.
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [Abstract] [Full Text] [Related]

  • 12. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z, Leqing C, Yazhen Q, Yu W, Xiaohui Z, Lanping X, Xiaojun H, Yingjun C.
    Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
    [Abstract] [Full Text] [Related]

  • 13. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
    Elmaagacli AH, Becks HW, Beelen DW, Stockova J, Bützler R, Opalka B, Schaefer UW.
    Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
    [Abstract] [Full Text] [Related]

  • 14. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K, Mitterbauer G, Mitterbauer M, Knöbl P, Schwarzinger I, Greinix HT, Rabitsch W, Fonatsch C, Mannhalter C, Lechner K, Jaeger U.
    Leuk Lymphoma; 2001 Dec; 42(5):923-31. PubMed ID: 11697647
    [Abstract] [Full Text] [Related]

  • 15. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
    Marcucci G, Caligiuri MA, Döhner H, Archer KJ, Schlenk RF, Döhner K, Maghraby EA, Bloomfield CD.
    Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
    [Abstract] [Full Text] [Related]

  • 16. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G, Hernandez A, Heyll A, Wolf HH, Wernet P.
    Cancer Detect Prev; 1996 Jul; 20(6):601-9. PubMed ID: 8939346
    [Abstract] [Full Text] [Related]

  • 17. Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation.
    Au WY, Lie AK, Lee CK, Liang R, Kwong YL.
    Bone Marrow Transplant; 1999 Jun; 23(11):1201-3. PubMed ID: 10382962
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

  • 19. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW, Wu DP, Zhu ZL, Wang W, Sun AN, Qiu HY, Fu ZZ, Chang WR, Ruan CG.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb 01; 25(2):78-81. PubMed ID: 14990044
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.